Upgrade to SI Premium - Free Trial

NewAmsterdam Pharma (NAMS)

21.16 -1.20 (5.37%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

NewAmsterdam Pharma CEO buys 10,000 shares at $22.65 September 15, 2026 4:37 PM - StreetInsider Form 4 NewAmsterdam Pharma Co For: Sep 14 Filed by: Davidson Michael H. September 15, 2026 4:30 PM - SEC Filing NewAmsterdam Pharma Co NV (NAMS) Reiterated at Buy by Stifel September 8, 2026 6:55 AM - StreetInsider NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 3, 2026 4:01 PM - StreetInsider NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September September 2, 2026 8:00 AM - StreetInsider NewAmsterdam Pharma (NAMS) call put ratio 1 call to 1 put on 3900 contracts August 31, 2026 5:32 AM - StreetInsider NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 August 26, 2026 8:00 AM - StreetInsider Form 4 NewAmsterdam Pharma Co For: Aug 24 Filed by: Kastelein Johannes Jacob Pieter August 25, 2026 4:30 PM - SEC Filing Form 3 NewAmsterdam Pharma Co For: Aug 10 Filed by: Gunning Robert William August 14, 2026 4:13 PM - SEC Filing NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 6, 2026 4:01 PM - StreetInsider NewAmsterdam Pharma Co NV (NAMS) PT Lowered to $50 at RBC Capital August 6, 2026 6:52 AM - StreetInsider NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results August 5, 2026 7:00 AM - StreetInsider NewAmsterdam Pharma to Host Investor Day on August 5, 2026 July 29, 2026 8:00 AM - StreetInsider EU panel backs NewAmsterdam and Menarini cholesterol drugs July 24, 2026 8:00 AM - StreetInsider NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Co July 24, 2026 8:00 AM - StreetInsider Form 4 NewAmsterdam Pharma Co For: Jul 20 Filed by: Kooij Louise Frederika July 22, 2026 4:05 PM - SEC Filing BMO Capital Starts NewAmsterdam Pharma Co NV (NAMS) at Outperform July 20, 2026 4:36 PM - StreetInsider Jefferies Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS) July 20, 2026 11:36 AM - StreetInsider Attovia Therapeutics names John Smither to board of directors July 15, 2026 8:30 AM - StreetInsider Attovia Therapeutics Appoints John W. Smither to Board of Directors July 15, 2026 8:30 AM - Globe NewsWire NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 2, 2026 4:01 PM - StreetInsider NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 July 1, 2026 8:00 AM - Globe NewsWire NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 July 1, 2026 8:00 AM - StreetInsider NewAmsterdam Pharma Co NV (NAMS) PT Raised to $51 at RBC Capital June 30, 2026 6:48 AM - StreetInsider Form 4 NewAmsterdam Pharma Co For: Jun 22 Filed by: Kooij Louise Frederika June 24, 2026 4:10 PM - SEC Filing NewAmsterdam Pharma (NAMS) call put ratio 1 call to 4.8 puts with a focus on 2K contracts of January 25 puts June 22, 2026 2:53 PM - StreetInsider Full Article List